Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation
Condition: Epilepsy
MeSH terms: Epilepsy
Intervention: BIA 2-093
Intervention MeSH terms: Eslicarbazepine acetate
Phase: Phase 1
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Single (Investigator)
Enrollment: 60.0
Sex: All
Minimum age: 18 Years
Maximum age: 55 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      Single center, randomized, single dose, laboratory-blinded, 2-period, 2-sequence, crossover
      design
    

Eligibility criteria:

        Inclusion Criteria:

          -  Availability of volunteer for the entire study period and willingness to adhere to
             protocol requirements as evidenced by the informed consent form (ICF) duly read,
             signed and dated by the volunteer

          -  Male or female aged of at least 18 years but not older than 55 years with a body mass
             index (BMI) greater than or equal to equal to 19 and below 30 kg/m2

          -  Clinical laboratory values within the laboratory's stated normal range; if not within
             this range, they must be without any clinical significance (laboratory tests are
             presented in section 6.1.1.3)

          -  Healthy according to the medical history, laboratory results and physical examination

          -  Light-, non- or ex-smokers. A light smoker is defined as someone smoking 10 cigarettes
             or less per day for at least 3 months before day 1 of this study. An exsmoker is
             defined as someone who completely stopped smoking for at least 12 months before day 1
             of this study

        Exclusion Criteria:

          -  Significant history of hypersensitivity to eslicarbazepine, oxcarbazepine,
             carbamazepine or any related products (including excipients of the formulations) as
             well as severe hypersensitivity reactions (like angioedema) to any drugs

          -  Presence of significant gastrointestinal, liver or kidney disease, or any other
             conditions known to interfere with the absorption, distribution, metabolism or
             excretion of drugs or known to potentiate or predispose to undesired effects

          -  History of significant gastrointestinal, liver or kidney disease, or surgery that may
             affect drug bioavailability, including but not limited to cholecystectomy

          -  Presence of significant cardiovascular, pulmonary, hematologic, neurologic,
             psychiatric, endocrine, immunologic or dermatologic disease

          -  Presence of significant heart disease or disorder according to ECG

          -  Presence or history of significant central nervous system disorder like convulsion or
             depression

          -  Participation in any previous study with eslicarbazepine acetate

          -  Females who are pregnant according to a positive serum pregnancy test or are lactating

          -  Females of childbearing potential who refuse to use an acceptable contraceptive
             regimen throughout the study

          -  Use of systemic contraceptives (oral, implant, etc.) in the previous 14 days before
             day 1 of this study and until study completion.

          -  Use of systemic contraceptives (injections) and hormonal replacement therapy in the
             previous 13 weeks before day 1 of this study and until study completion

          -  Maintenance therapy with any drug, or significant history of drug dependency or
             alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or
             chronic)

          -  Any clinically significant illness in the previous 28 days before day 1 of this study

          -  Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,
             fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP
             enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin and
             rifampin), in the previous 28 days before Day 1 of this study

          -  Participation in another clinical trial or donation of 50 mL or more of blood in the
             previous 28 days before day 1 of this study

          -  Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical
             studies, etc.) in the previous 56 days before day 1 of this study

          -  Positive urine screening of drugs of abuse (drugs listing is presented in section
             6.1.1.4)

          -  Any history of tuberculosis and/or prophylaxis for tuberculosis

          -  Positive results to HIV, HBsAg or anti-HCV tests